Get the Stockscreener App
185.39
7.58%
13.07
After Hours:
185.39
Charles River Laboratories International Inc stock is traded at $185.39, with a volume of 1.17M.
It is up +7.58% in the last 24 hours and up +6.61% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$172.32
Open:
$174.68
24h Volume:
1.17M
Relative Volume:
1.18
Market Cap:
$9.15B
Revenue:
$4.02B
Net Income/Loss:
$-142.16M
P/E Ratio:
-62.71
EPS:
-2.9563
Net Cash Flow:
$518.49M
1W Performance:
+11.15%
1M Performance:
+6.61%
6M Performance:
+10.55%
1Y Performance:
+55.22%
1-Day Range:
$172.42
$185.57
1-Week Range:
$161.95
$185.57
52-Week Range:
$113.89
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
185.39 | 8.50B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
How Charles River’s Expanded Rat IVF Platform Could Reshape CRL’s Preclinical Services Mix and Investor View - Sahm
MSN Money - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River (NYSE: CRL) CFO receives 21,112-share stock award - Stock Titan
Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight - GlobeNewswire Inc.
Charles River Gears Up for Q1 Earnings: What's in the Cards? - Yahoo Finance
Charles River Laboratories (CRL) Stock Report: Analyst Consensus and 20% Upside Potential - DirectorsTalk Interviews
LaPlume buys Charles River Labs [CRL] shares worth $4363 - Investing.com
Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
What you need to know ahead of Charles River Laboratories' earnings release - MSN
Vanguard Group Inc. Purchases 47,432 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Weakness And Diverging Fair Value Views - simplywall.st
CRL Stock Price, Quote & Chart | CHARLES RIVER LABORATORIES (NYSE:CRL) - ChartMill
Charles River (CRL) Introduces New In Vitro Fertility Service Bu - GuruFocus
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
First commercial rat IVF service targets breeding bottlenecks - Stock Titan
Pekin Hardy Strauss Inc. Lowers Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories Stock: Q1 2026 Earnings Release Scheduled for April 30 - AD HOC NEWS
Charles River Laboratories International (CRL) Projected to Post Earnings on Thursday - MarketBeat
Charles River gains new outperform at RBC despite NAMs related disruption - MSN
Vanguard (NYSE: CRL) reports 7.38% ownership of Charles River shares - Stock Titan
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's why Charles River Laboratories (CRL) is a strong value stock - MSN
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River appoints Birgit Girshick as incoming CEO as long-serving chief prepares to step down - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
Here's Why Charles River Laboratories (CRL) is a Strong Value Stock - Yahoo Finance
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement - MSN
Why is Charles River (CRL) down 6.8% since last earnings report? - MSN
Charles River announces divestitures, updates guidance - MSN
CROs fall as FDA head Makary says drug approvals will require fewer trials - MSN
M&T Bank Corp Grows Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):